title: Clinical outcomes of chronic kidney disease patients treated with everolimus-eluting stents (EES) and paclitaxel-eluting stents (PES).
abstract: BACKGROUND
  The target lesion revascularization of paclitaxel-eluting stents (PES) has been reported to be lower than that of sirolimus-eluting stents in patients on hemodialysis (HD). However, the comparison of PES and second generation drug-eluting stents in CKD patients has not been fully investigated. We compared clinical outcomes of everolimus-eluting stents (EES) and PES in CKD patients.
  
  
  METHODS
  Hundred and forty seven CKD patients (eGFR<60mLmin(-1)1.73m(-2)) treated with PES (n=74, from May 2007 to December 2009) and EES (n=73, from January 2010 to January 2013) were enrolled in the study. Major adverse cardiac events (MACEs) were defined as death, non-fatal myocardial infarction, and ischemia driven target lesion revascularization.
  
  
  RESULTS
  The incidence of 36-month MACE was significantly lower in EES, non-HD group compared to PES, non HD group (0% in EES group and 13.5% in PES group, respectively, P<0.01). There was no significant difference in MACE between EES and PES in HD patients (5.4% in PES group and 5.5% in EES group, P=0.98). In multivariate analysis, PES group and PES ISR were independent factors for worse incidence of MACE.
  
  
  CONCLUSIONS
  In CKD patients, PES was associated with worse clinical outcomes in non-HD patients as compared with EES.
authors.affiliation: Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan. Electronic address: lisa@med.kitasato-u.ac.jp.
authors.forename: Lisa
authors.initials: L
authors.lastname: Kitasato
authors.affiliation: Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan. Electronic address: takshimo@med.kitasato-u.ac.jp.
authors.forename: Takao
authors.initials: T
authors.lastname: Shimohama
authors.affiliation: Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan. Electronic address: y_ikeda@med.kitasato-u.ac.jp.
authors.forename: Yuki
authors.initials: Y
authors.lastname: Ikeda
authors.affiliation: Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan. Electronic address: sayakayasa@med.kitasato-u.ac.jp.
authors.forename: Sayaka
authors.initials: S
authors.lastname: Namba
authors.affiliation: Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan. Electronic address: t_hashikata@med.kitasato-u.ac.jp.
authors.forename: Takehiro
authors.initials: T
authors.lastname: Hashikata
authors.affiliation: Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan. Electronic address: rkameda@med.kitasato-u.ac.jp.
authors.forename: Ryo
authors.initials: R
authors.lastname: Kameda
authors.affiliation: Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan. Electronic address: hokkaidou_yamakosigun_@hotmail.com.
authors.forename: Nobuhiro
authors.initials: N
authors.lastname: Sato
authors.affiliation: Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan. Electronic address: itake@myad.jp.
authors.forename: Ichiro
authors.initials: I
authors.lastname: Takeuchi
authors.affiliation: Department of Rehabilitation, Kitasato University School of Allied Health Sciences, Sagamihara, Japan. Electronic address: myamaoka@med.kitasato-u.ac.jp.
authors.forename: Minako
authors.initials: M
authors.lastname: Yamaoka-Tojo
authors.affiliation: Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan. Electronic address: ttojo@med.kitasato-u.ac.jp.
authors.forename: Taiki
authors.initials: T
authors.lastname: Tojo
authors.affiliation: Kitasato University Graduate School of Medical Sciences, Sagamihara, Japan; Department of Cardiovascular Medicine, Kitasato University School of Medicine, Sagamihara, Japan. Electronic address: jako@kitasato-u.ac.jp.
authors.forename: Junya
authors.initials: J
authors.lastname: Ako
mesh_terms: D000284:Administration, Oral; D000368:Aged; D002318:Cardiovascular Diseases / Q000139:chemically induced / Q000000981:diagnostic imaging; D017023:Coronary Angiography; D054855:Drug-Eluting Stents / Q000009:adverse effects; D000068338:Everolimus / Q000009:adverse effects / Q000627:therapeutic use*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D053208:Kaplan-Meier Estimate; D008297:Male; D015999:Multivariate Analysis; D017239:Paclitaxel / Q000009:adverse effects / Q000627:therapeutic use*; D062645:Percutaneous Coronary Intervention; D016016:Proportional Hazards Models; D006435:Renal Dialysis; D051436:Renal Insufficiency, Chronic / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000068338:Everolimus; D017239:Paclitaxel
keywords: Chronic kidney disease; Everolimus-eluting stent; Paclitaxel-eluting stent